Veradigm Yönetim

Yönetim kriter kontrolleri 2/4

Veradigm CEO'su Tom Langan, May2022 tarihinde atandı, in görev süresi 2.5 yıldır. şirketin hisselerinin 0.2% doğrudan sahiptir ve bu hisselerin değeri $ 3.54M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 6.5 yıldır.

Anahtar bilgiler

Tom Langan

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.5yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	6.5yrs

Son yönetim güncellemeleri

Recent updates

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 22

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Jan 04

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

Dec 03

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Sep 28

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Sep 17

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

Aug 24

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt

Jul 31

Is Now An Opportune Moment To Examine Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?

Jun 15

We Like These Underlying Return On Capital Trends At Allscripts Healthcare Solutions (NASDAQ:MDRX)

May 03

CEO

Tom Langan (58 yo)

2.5yrs

Görev süresi

Mr. Thomas J. Langan, also known as Tom, serves as CEO of Veradigm Inc. since June 7, 2024. He serves as President at Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc.) since May 06, 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
P. Garrison	Executive Chairman of the Board	9.3yrs	US$303.00k	0.044% $ 804.3k
Tejal Vakharia	Senior VP of Marketing & Government Affairs	4.4yrs	US$2.08m	0.12% $ 2.2m
Thomas Langan	President & Chief Commercial Officer and Interim CEO	2.5yrs	Veri yok	0.20% $ 3.5m
Leland Westerfield	Interim CFO and Principal Financial & Accounting Officer	less than a year	Veri yok	Veri yok
Jenny Gelinas	Vice President of Investor Relations	3.8yrs	Veri yok	Veri yok
Richard Elmore	Senior Vice President of Corporate Development & Strategy	5.8yrs	Veri yok	Veri yok
Lisa Hammond	Senior VP & Chief Human Resources Officer	3.5yrs	Veri yok	0.015% $ 265.3k
John Sage	Senior Vice President of U.S. Hospitals & Health Systems Sales	9.9yrs	Veri yok	Veri yok
Elliot Bryant	Senior VP & General Manager for Classic Client Solutions Business Unit	4.3yrs	Veri yok	Veri yok
John Mayr	Senior Vice President of Global Client Delivery Organization	2.8yrs	Veri yok	Veri yok
Alan Fowles	President of Allscripts International	7.8yrs	Veri yok	Veri yok
Eric Jacobson	Senior VP & Corporate Secretary	no data	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: MDRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
P. Garrison	Executive Chairman of the Board	9.3yrs	US$303.00k	0.044% $ 804.3k
Jonathan Judge	Independent Director	8.5yrs	US$301.00k	0.091% $ 1.6m
Carol Zierhoffer	Lead Independent Director	4.3yrs	US$277.50k	0.037% $ 675.1k
David Stevens	Independent Director	8.5yrs	US$281.50k	0.032% $ 569.7k
Kim Franks	Member of Advisory Board	no data	Veri yok	Veri yok
Elizabeth Altman	Independent Director	4.4yrs	US$277.50k	0.033% $ 603.5k
Susan Rodriguez	Director	1.8yrs	Veri yok	0.012% $ 224.5k
Jeanne Armstrong	Member of Advisory Board	no data	Veri yok	Veri yok
Geoff Caplea	Member of Advisory Board	no data	Veri yok	Veri yok
Laura Kohlhagen	Member of Advisory Board	no data	Veri yok	Veri yok
Debbie McKay	Member of Advisory Board	no data	Veri yok	Veri yok
Ramanujam Venugopalan	Member of Advisory Board	no data	Veri yok	Veri yok

6.5yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MDRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.5 yıldır).

Veradigm Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Veradigm Inc. Announces Interim Chief Executive Officer Changes

Veradigm Inc. Announces CEO Changes

Veradigm Inc. Announces CEO Changes

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Recent updates

Veradigm Inc. announced delayed 10-Q filing

McKesson, Oracle, Thoma Bravo Reportedly Among Finalists to Acquire Veradigm

Veradigm Inc. announced delayed 10-Q filing

Holmusk and Veradigm Reach New Data Enrichment Milestone in Strategic Collaboration

Veradigm Inc. Is Reaffirms Earnings Guidance for Fiscal 2024

Veradigm Inc. Announces Interim Chief Executive Officer Changes

Veradigm Inc. announced delayed 10-Q filing

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Notify the Nasdaq's Determination to Delist Veradigm's Securities from Listing

Veradigm Inc. Provides Earnings Guidance for the Fiscal Year 2024

Veradigm Inc. (OTCPK:MDRX) completed the acquisition of Cascade Bio, Inc

Veradigm Inc. announced delayed annual 10-K filing

Veradigm Inc.(OTCPK:MDRX) dropped from NASDAQ Composite Index

Veradigm Receives Expected Delisting Notice from Nasdaq

Investor sentiment deteriorates as stock falls 18%

Veradigm Inc. signed a definitive agreement to acquire Cascade Bio, Inc.

Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share Price

Price target decreased by 12% to US$14.33

Veradigm Inc. Revises Earnings Guidance for the Fiscal 2023

Robbins Geller Rudman & Dowd LLP Files Amended Class Action Lawsuit Against Veradigm Inc

Nasdaq Hearings Panel Grants Veradigm's Request for Continued Listing on the Nasdaq Capital Market, Subject to Demonstrating Compliance with Nasdaq Listing Rule 5250(C)(1) on or Before February 27, 2024

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Veradigm Inc

Veradigm Inc. to Enhance Independent Practice Financial Management with AI for Practice Fusion Billing Services

Veradigm Inc. Announces CEO Changes

Veradigm Inc. Announces CEO Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Veradigm Inc

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Veradigm Inc

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q

Veradigm Inc. announced delayed 10-Q filing

Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-Bagger

Veradigm to Simplify Patient Payment Journey with Veradigm Intelligent Payments

Veradigm Inc. Announces Receipt of Nasdaq Stay Extension

Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal

Veradigm Inc. Provides Revenue Guidance for the Fiscal Year 2023

Veradigm Inc. announced delayed 10-Q filing

Veradigm Receives Approval from Nasdaq Regarding its Plan to Regain Compliance with Nasdaq Listing Rule 5250(c)(1)

Veradigm Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Veradigm Inc. announced delayed 10-Q filing

Price target decreased by 7.1% to US$19.19

Price target decreased by 9.1% to US$20.07

Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher

Investor sentiment deteriorates as stock falls 15%

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?

Consensus EPS estimates fall by 11%

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Veradigm Inc. to Report Q4, 2022 Results on Feb 23, 2023

LeanTaaS Inc. acquired Hospital IQ, Inc.

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Insider notifies of intention to sell stock

Independent Director recently sold US$797k worth of stock

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Third quarter 2022 earnings: EPS misses analyst expectations

Allscripts Healthcare Solutions, Inc. Provides Revenue Guidance for the Year 2022

Allscripts Healthcare Solutions, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Chief Financial Officer recently sold US$116k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer recently sold US$70k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: US$0.028 (vs US$0.16 in 2Q 2021)

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt